[HTML][HTML] 2018 Korean Liver Cancer Association–National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association - Korean Journal of Radiology, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
Treatment and the prognosis of hepatocellular carcinoma in Asia
T Torimura, H Iwamoto - Liver International, 2022 - Wiley Online Library
Hepatocellular carcinoma is the most common type of malignant tumour in Asia. Treatment
is decided according to the staging system with information on tumour burden and liver …
is decided according to the staging system with information on tumour burden and liver …
[HTML][HTML] 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association - Korean Journal of Radiology, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
[HTML][HTML] Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
JE Song - World journal of hepatology, 2017 - ncbi.nlm.nih.gov
Transarterial chemoembolization (TACE) is the current standard of therapy for patients with
intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
[PDF][PDF] Update on transarterial chemoembolization with drug-eluting microspheres for hepatocellular carcinoma
YM Nouri, JH Kim, HK Yoon, HK Ko… - Korean Journal of …, 2019 - synapse.koreamed.org
Conventional transcatheter arterial chemoembolization (c-TACE) is a widely used first-line
palliative treatment for patients with unresectable hepatocellular carcinoma (HCC). Despite …
palliative treatment for patients with unresectable hepatocellular carcinoma (HCC). Despite …
2018 Korean Liver Cancer Association–National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association … - Korean Journal of …, 2019 - synapse.koreamed.org
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America: Summary of key guidelines for locoregional treatment of HCC …
RD Garcia-Monaco, JW Chung… - The British Journal of …, 2022 - academic.oup.com
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide accounting for
over 800,000 new cases in 2018, with the highest incidence in Asia and Africa where …
over 800,000 new cases in 2018, with the highest incidence in Asia and Africa where …
Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating barcelona clinic liver cancer stage 0/A hepatocellular …
YJ Kang, BC Lee, JK Kim, NY Yim, HO Kim… - CardioVascular and …, 2020 - Springer
Abstract Purpose Approximately, 60–70% of patients with early-stage hepatocellular
carcinoma (HCC) globally are ineligible for the recommended first-line procedures. This …
carcinoma (HCC) globally are ineligible for the recommended first-line procedures. This …
Recent advances in targeted therapy for inflammatory vascular diseases
K Zhao, Z Zeng, Y He, R Zhao, J Niu, H Sun, S Li… - Journal of Controlled …, 2024 - Elsevier
Vascular diseases constitute a significant contributor to worldwide mortality rates, placing a
substantial strain on healthcare systems and socio-economic aspects. They are closely …
substantial strain on healthcare systems and socio-economic aspects. They are closely …